American Journal of Kidney Diseases
Volume 55, Issue 2 , Pages 344-347 , February 2010

Successful Treatment With Retinoids in Patients With Lupus Nephritis

Received 18 March 2009 ,Accepted 8 June 2009.

References 

  1. Walsh SJ, Algert C, Gregorio DI, Reisine ST, Rothfield NF. Divergent racial trends in mortality from systemic lupus erythematosus. J Rheumatol. 1995;22:1663–1668
  2. Steinberg AD, Steinberg SC. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum. 1991;34:945–950
  3. Pryor BD, Bologna SG, Kahl LE. Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus. Arthritis Rheum. 1996;39:1475–1482
  4. Baker GL, Kahl LE, Zee BC, Stolzer BL, Agarwal AK, Medsger TA. Malignancy following treatment of rheumatoid arthritis with cyclophosphamide (Long-term case-control follow-up study). Am J Med. 1987;83:1–9
  5. Paillaud E, Costa S, Fages C, et al. Retinoic acid increases proliferation rate of GL-15 glioma cells, involving activation of STAT-3 transcription factor. J Neurosci Res. 2002;67:670–679
  6. Kinoshita K, Yoo BS, Nozaki Y, et al. Retinoic acid reduces autoimmune renal injury and increases survival in NZB/W F1 mice. J Immunol. 2003;170:5793–5798
  7. Wagner J, Dechow C, Morath C, et al. Retinoic acid reduces glomerular injury in a rat model of glomerular damage. J Am Soc Nephrol. 2000;11:1479–1487
  8. Suzuki A, Ito T, Imai E, et al. Retinoids regulate the repairing process of the podocytes in puromycin aminonucleoside-induced nephrotic rats. J Am Soc Nephrol. 2003;14:981–991
  9. Oseto S, Moriyama T, Kawada N, et al. Therapeutic effect of all-trans retinoic acid on rats with anti-GBM antibody glomerulonephritis. Kidney Int. 2003;64:1241–1252
  10. Huang ME, Ye YC, Chen SR, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 1988;72:567–572
  11. Ward A, Brogden RN, Heel RC, Speight TM, Avery GS. Etretinate (A review of its pharmacological properties and therapeutic efficacy in psoriasis and other skin disorders). Drugs. 1983;26:9–43
  12. Peck GL, Olsen TG, Butkus D, et al. Isotretinoin versus placebo in the treatment of cystic acne (A randomized double-blind study). J Am Acad Dermatol. 1982;6:735–745
  13. Brinckerhoff CE. Retinoids and rheumatoid arthritis: Modulation of extracellular matrix by controlling expression of collagenase. Methods Enzymol. 1990;190:175–188
  14. Nozaki Y, Yamagata T, Yoo BS, et al. The beneficial effects of treatment with all-trans-retinoic acid plus corticosteroid on autoimmune nephritis in NZB/WF mice. Clin Exp Immunol. 2005;139:74–83
  15. Morath C, Dechow C, Lehrke I, et al. Effects of retinoids on the TGF-beta system and extracellular matrix in experimental glomerulonephritis. J Am Soc Nephrol. 2001;12:2300–2309
  16. Moreno-Manzano V, Mampaso F, Sepulveda-Munoz JC, et al. Retinoids as a potential treatment for experimental puromycin-induced nephrosis. Br J Pharmacol. 2003;139:823–831
  17. Datta PK, Lianos EA. Retinoic acids inhibit inducible nitric oxide synthase expression in mesangial cells. Kidney Int. 1999;56:486–493
  18. Schaier M, Jocks T, Grone HJ, Ritz E, Wagner J. Retinoid agonist isotretinoin ameliorates obstructive renal injury. J Urol. 2003;170:1398–1402
  19. Pilkington T, Brogden RN. Acitretin (A review of its pharmacology and therapeutic use). Drugs. 1992;43:597–627

 Originally published online as doi:10.1053/j.ajkd.2009.06.012 on July 24, 2009.

PII: S0272-6386(09)00875-0

doi: 10.1053/j.ajkd.2009.06.012

American Journal of Kidney Diseases
Volume 55, Issue 2 , Pages 344-347 , February 2010

Article Tools

* Image Usage & Resolution